Autolus Therapeutics plc
AUTL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001730463
In the last 90 days, Autolus Therapeutics plc insiders filed 0 open-market purchases and 1 sale; 83 institutions reported holding it in 13F filings for Q2 2026, worth $212.0M in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Autolus Therapeutics plc changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 63 | 69 | +6 |
| Shares | 22.5M | 25.4M | +2.86M (+12.7%) |
| Value | $129.4M | $169.6M | +$40.2M (+31.1%) |
New holders (23)
Institutions that held Autolus Therapeutics plc at the end of Q2 2021 but not at the end of Q1 2021.
Sold out (17)
Institutions that held Autolus Therapeutics plc at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Capital International Investors | 2,272,728 | $13.0M |
| Deerfield Management Company, L.P. (Series C) | 2,142,857 | $12.3M |
| Opaleye Management Inc. | 2,112,918 | $12.1M |
| Baker Bros. Advisors LP | 461,726 | $2.65M |
| Caas Capital Management LP | 223,366 | $1.28M |
| Laurion Capital Management LP | 152,847 | $876.0K |
| Squarepoint Ops LLC | 82,602 | $473.0K |
| Renaissance Technologies LLC | 81,588 | $467.0K |
| Two Sigma Investments, LP | 77,140 | $442.0K |
| California Public Employees Retirement System | 40,600 | $233.0K |
| Nomura Holdings Inc | 30,000 | $165.0K |
| Two Sigma Advisers, LP | 13,900 | $80.0K |
| Natixis | 12,600 | $72.0K |
| Victory Capital Management Inc | 6,014 | $34.0K |
| Sowell Financial Services LLC | 1,500 | $8.00K |
| Total Clarity Wealth Management, Inc. | 1,000 | $6.00K |
| Bank of Montreal | 145 | $1.00K |